Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Mulpleo

- PMLiVE

Shionogi to acquire Qpex Biopharma for approximately $140m

The deal signifies a notable expansion to the Japanese drugmaker’s antimicrobial pipeline

- PMLiVE

Shionogi’s cefiderocol shows efficacy against difficult-to-treat bacterial infections

Antimicrobial resistance has been declared as one of the top ten threats to global health

- PMLiVE

European MPs call for urgent action against antimicrobial resistance

It is estimated that AMR could lead to as many as ten million deaths each year by 2050

- PMLiVE

Shionogi signs licence agreement with MPP for COVID-19 oral antiviral treatment

The agreement aims to increase access to ensitrelvir in low- and middle-income countries

- PMLiVE

Shionogi’s antiviral COVID-19 treatment meets phase 3 primary endpoint

Ensitrelvir reduced the time taken to resolve five key symptoms

- PMLiVE

Shionogi, GARDP and CHAI team up to increase antibiotic access worldwide

The licence and collaboration agreements will provide 135 countries access to cefiderocol

- PMLiVE

MHRA approves Infex Therapeutics’s study for treatment for non-cystic fibrosis patients

The treatment, for Pseudomonas aeruginosa, will address a chronic and debilitating respiratory condition that has no approved available treatments

- PMLiVE

Shionogi and F2G partner to develop antifungal treatment olorofim

The deal, worth up to $480m, involves the first novel antifungal treatment developed in the last 20 years

- PMLiVE

NHS to offer two new treatments for drug-resistant superbugs as part of a new subscription-style payment plan

Manufacturers will receive a fixed yearly fee of £10m, instead of receiving individual payments per dose

- PMLiVE

UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

The antibiotic treats infections caused by aerobic Gram-negative bacteria

- PMLiVE

Shionogi’s novel antibiotic trial data published in The Lancet

Data from APEKS-NP and CREDIBLE-CR studies published

- PMLiVE

Shionogi’s Gram-negative antibiotic launches in the UK

Novel antibiotic is indicated for use against Gram-negative bacterial infections

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links